Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Feb 10, 2026
Starbucks (SBUX) Stock Analysis: Turnaround Momentum Gains Traction

Starbucks (SBUX) Stock Analysis: Turnaround Momentum Gains Traction

Key Takeaways

  • Starbucks (SBUX) delivered solid Q1 fiscal 2026 results, with revenue rising 6% year over year to $9.9 billion and global comparable store sales up 4%, driven by higher transactions.

  • U.S. transaction growth turned positive for the first time in eight quarters, signaling early success of the “Back to Starbucks” turnaround strategy.

  • Management outlined long-term growth initiatives at its January 29 Investor Day, including loyalty program enhancements and coffeehouse experience upgrades.

  • FY2026 guidance calls for at least 3% global and U.S. comparable sales growth, alongside 600–650 net new store openings.

  • The stock has rebounded roughly 10% in recent weeks, trading near $96.65 with a market capitalization above $110 billion.

  • Analysts maintain a Moderate Buy consensus, with average price targets clustered around $99.

Current Market Snapshot

Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers. Trading around $96, SBUX continues to benefit from its global scale and powerful brand equity, even as it navigates competitive intensity and cost pressures across the consumer landscape. Overall investor sentiment has turned more constructive on the outlook for sustained top-line momentum.

Recent Developments Driving SBUX Price Action

Starbucks’ recent price volatility has been closely tied to its fiscal Q1 2026 earnings release on January 28 and the subsequent Investor Day on January 29. The company reported net revenues of $9.9 billion, up 6% year over year and ahead of expectations. Global comparable store sales increased 4%, matching U.S. growth and driven primarily by higher transactions—marking the first positive U.S. transaction growth in eight quarters.

Non-GAAP EPS came in at $0.56, down 19% year over year, reflecting restructuring charges and tax impacts related to classifying China operations as held for sale. Despite the EPS decline, investors focused on improving sales trends, sending the stock 5–8% higher in the sessions following the report.

The results reinforced confidence in CEO Brian Niccol’s “Back to Starbucks” strategy, which centers on reviving coffeehouse culture, improving speed of service through menu simplification, and reinvesting in labor via initiatives such as the Green Apron model. Investor Day further supported the bullish narrative, highlighting a revamped loyalty program designed to reward visit frequency, coffeehouse innovations, and a financial framework targeting sustainable growth. Management emphasized that execution is running ahead of plan, with rising U.S. partner engagement and growth in non-Rewards transactions.

Another strategic catalyst has been the company’s announced plan to form a joint venture with Boyu Capital for its China business, with Starbucks retaining a 40% stake. Expected to close in spring 2026 pending regulatory approvals, the move aims to sharpen Starbucks’ competitive positioning against value-focused rivals such as Luckin Coffee. FY2026 guidance assumes company-operated China stores in the second half of the year and includes at least 3% comparable sales growth globally and in the U.S., 600–650 net new stores—roughly half internationally—and modest operating margin expansion in the back half as investments annualize.

Additional operational updates included the January appointment of Anand Varadarajan as Chief Technology Officer to accelerate digital and efficiency initiatives, along with menu streamlining efforts such as reducing Frappuccino offerings and adding protein-forward items. While labor tensions persist amid union-led actions, U.S. comparable sales still rose 4%, suggesting consumer demand has outweighed the noise. Analyst reactions have been mixed but improving, with Citi raising its price target to $94 from $83 and BWG upgrading the stock, even as some firms remain cautious. Collectively, these developments have supported a roughly 10% rebound in the stock from the low $80s to the high $90s.

2026 Outlook and Key Factors to Watch

As Starbucks progresses through fiscal 2026, investor attention will center on execution of the “Back to Starbucks” strategy. Key benchmarks include sustaining at least 3% comparable sales growth globally and in the U.S., delivering 600–650 net new stores with an emphasis on international markets, and stabilizing U.S. traffic trends. The anticipated China joint venture with Boyu Capital will be a critical milestone, potentially modestly dilutive to EPS but offering strategic flexibility and renewed growth optionality in a challenging market.

Margin performance will also be closely watched, with modest improvement expected in the second half as labor and technology investments mature, partially offsetting inflation in wages and coffee costs. Loyalty program enhancements, menu simplification, and technology-driven efficiency gains under new CTO leadership remain central to the turnaround thesis.

Risks include ongoing labor unrest, macro-driven shifts in consumer spending, commodity price volatility, and intense competition—particularly in China. Progress in sustainability initiatives and brand perception as a premium coffee destination may further shape long-term outcomes. Balanced execution across these dimensions will determine whether Starbucks can convert its early momentum into durable earnings growth and shareholder value creation.

Tickeron AI Perspective

Disclaimers and Limitations

Related Ticker: SBUX

SBUX in +2.67% Uptrend, advancing for three consecutive days on July 30, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where SBUX advanced for three days, in of 297 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 65 cases where SBUX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 187 cases where SBUX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SBUX as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for SBUX turned negative on July 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SBUX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

SBUX broke above its upper Bollinger Band on July 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (6.230). P/E Ratio (59.751) is within average values for comparable stocks, (39.574). Projected Growth (PEG Ratio) (1.257) is also within normal values, averaging (1.783). Dividend Yield (0.024) settles around the average of (0.027) among similar stocks. P/S Ratio (3.081) is also within normal values, averaging (2.368).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SBUX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SBUX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.

Notable companies

The most notable companies in this group are McDonald's Corp (NYSE:MCD), Starbucks Corp (NASDAQ:SBUX), Chipotle Mexican Grill (NYSE:CMG), Yum! Brands (NYSE:YUM), Darden Restaurants (NYSE:DRI), Yum China Holdings (NYSE:YUMC), Dominos Pizza Inc (NASDAQ:DPZ), Shake Shack (NYSE:SHAK), Noodles & Co (NASDAQ:NDLS).

Industry description

The industry includes companies that operate full-service restaurants, fast food restaurants, cafeterias and snack bars. McDonald`s Corporation, Starbucks Corporation, YUM! Brands, Inc. and Restaurant Brands International Inc. are some of the largest U.S. restaurant-owning companies in terms of market capitalization. While restaurant spending could be viewed as discretionary for consumers, some companies in the business have been able to weather economic cycles by establishing strong loyalty among customers over the years. Many of them also have a strong global presence as well.

Market Cap

The average market capitalization across the Restaurants Industry is 10.51B. The market cap for tickers in the group ranges from 2.74K to 188.45B. MCD holds the highest valuation in this group at 188.45B. The lowest valued company is BFICQ at 2.74K.

High and low price notable news

The average weekly price growth across all stocks in the Restaurants Industry was 2%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was 9%. NDLS experienced the highest price growth at 30%, while CCHH experienced the biggest fall at -20%.

Volume

The average weekly volume growth across all stocks in the Restaurants Industry was 20%. For the same stocks of the Industry, the average monthly volume growth was -8% and the average quarterly volume growth was -35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 57
Price Growth Rating: 57
SMR Rating: 69
Profit Risk Rating: 85
Seasonality Score: -37 (-100 ... +100)
View a ticker or compare two or three
SBUX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a producer of coffee and tea

Industry Restaurants

Profile
Details
Industry
Restaurants
Address
2401 Utah Avenue South
Phone
+1 206 447-1575
Employees
381000
Web
https://www.starbucks.com
Interact to see
Advertisement
Chevron’s upcoming Q4 report highlights its first full quarters integrating Hess, following record Q3 production of 4.1 million barrels of oil equivalent per day (MMboe/d). Comparing CVX with ExxonMobil and Shell provides insight into how each supermajor is navigating a volatile oil market with prices hovering below $60 per barrel.
SoFi Technologies is set to report Q4 and full-year 2025 earnings on January 30, 2026, closing out a pivotal year for the digital finance platform. With its fiscal year ending December 31, the report follows a strong Q3 that featured record net revenue of $962 million and member growth to 12.6 million, a 35% year-over-year increase.
ASML reported Q4 2025 net sales of $9.7 billion, gross margin of 52.2%, net income of $2.8 billion, and record net bookings of $13.2 billion, including $7.4 billion in EUV orders.
IDEXX Laboratories (IDXX) reports Q4 2025 earnings on February 2, 2026, with analysts expecting continued strength in recurring revenue from companion animal diagnostics. Danaher (DHR) reports on January 28, while Thermo Fisher Scientific (TMO) follows in early February, with both facing low-single-digit core growth expectations across life sciences and diagnostics.
NIO Inc. (NIO) produced its one-millionth vehicle this week at its Hefei facility, closing out a record 2025 delivery total of 326,028 units, up 46.9% year over year. The milestone, announced January 6, reflects accelerating demand for core models such as the ES8 SUV and newer brands ONVO and Firefly.
Faraday Future Intelligent Electric Inc. (FFAI) shares traded near $1.02 this week following announcements of a non-binding $10 million stock purchase term sheet with AIxCrypto (AIxC) and preparations for a Stockholders’ Day on January 7, 2026. Trading volume spiked amid broader EV volatility, highlighting investor attention on FFAI’s pivot toward AI-enhanced mobility and robotics.
BTQ Technologies Corp. (BTQ), formerly BTQQF, launched the Bitcoin Quantum testnet this week—the first quantum-safe Bitcoin fork, 17 years after Bitcoin’s genesis block. The move coincided with inclusion in the $524.5 million VanEck Quantum Computing UCITS ETF, boosting European investor visibility.
VEU targets large- and mid-cap ex-U.S. stocks with ~3,800 holdings. VXUS offers broad all-cap exposure, including ~8,600 stocks across small-, mid-, and large-cap companies.
Apple (AAPL) reports Q1 FY2026 earnings on January 29, with consensus revenue at $138.5B and EPS at $2.67, supported by strong demand for iPhone 17 models, higher average selling prices, and continued Services growth. Microsoft (MSFT) reports Q2 FY2026 on January 28, expecting $80.3B revenue and $3.91 EPS, driven by Azure AI adoption and enterprise cloud expansion, though elevated capex spending (~$35B/quarter) remains under scrutiny.
Visa Inc. (V), the global payments network leader, reports Q1 FY2026 earnings on January 29, 2026, for the period ending December 31, 2025. This marks the start of FY2026 following a strong FY2025, where net revenue reached $40 billion (+11%) and EPS climbed to $11.47 (+14%). Investors are watching closely for insights into consumer spending, cross-border travel recovery, and digital payment adoption.
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.